A 52-week study involving individuals with late-life depression found that participants who took omega-3 polyunsaturated fatty acid supplements experienced improved processing speed and reduced brain entropy in several brain regions compared to the placebo group. The paper was published in the Journal of Affective Disorders.
Late-life depression refers to depression that occurs in older adults, typically those aged 60 and older. It can be a result of various factors, including chronic illnesses, social isolation, loss of loved ones, and changes in life circumstances. Late-life depression can manifest differently from depression in younger individuals, with symptoms such as memory problems, physical complaints, and a lack of motivation being more prominent.
This condition can have a profound impact on an individual’s physical health, increasing the risk of heart disease, weakening the immune system, and exacerbating existing health problems. Socially, it can lead to isolation and a decrease in the quality of life, as older adults may withdraw from social interactions and activities they once enjoyed.
Late-life depression often also results in cognitive impairments like memory loss or difficulty concentrating. Studies indicate that individuals suffering from this type of depression have almost double the odds of developing dementia.
Study author Chemin Lin and his colleagues wanted to explore whether omega-3 polyunsaturated fatty acid supplements could help mitigate cognitive impairments in individuals suffering from late-life depression. Omega-3 polyunsaturated fatty acids are essential fats that the human body cannot produce on its own. They are found in foods like fish, flaxseed, and walnuts, and are important for heart health, brain function, and reducing inflammation.
Prior research has demonstrated that omega-3 supplements can significantly lower depressive symptoms (with doses over 1.5 grams per day), improve inflammation markers, and offer additional health benefits. The study authors hypothesized that these supplements could also reduce cognitive impairments in those with late-life depression and designed an experiment to test this theory.
The study included 20 participants over 60 years old who had experienced at least one depressive episode after 55. They were divided into two groups without being informed of their group assignment. One group received capsules containing 2.2 grams of omega-3 polyunsaturated fatty acids daily for 52 weeks, while the control group received capsules with soybean oil.
Throughout the study, participants underwent assessments and received capsules at seven intervals. Assessments included evaluations of general illness symptoms, sleep quality, loneliness, and cognitive function tests, along with blood samples for inflammation markers and magnetic resonance imaging.
Results showed that cognitive processing speed improved in the group taking omega-3 polyunsaturated fatty acid supplements, while remaining unchanged in the group that was taking soybean oil capsules. Inflammatory markers and other domains of cognitive functioning were unaffected by these supplements.
Furthermore, the omega-3 group exhibited reduced brain entropy in various brain regions, indicating a potential mechanism through which omega-3 polyunsaturated fatty acids could counteract cognitive decline in late-life depression through anti-inflammatory actions and brain entropy modulation. The authors call for larger clinical trials to confirm the therapeutic potential of omega-3 supplements for individuals with late-life depression.
“These findings suggest that omega-3 PUFAs [polyunsaturated fatty acid) supplement may mitigate cognitive decline in LLD [late-life depression] through anti-inflammatory mechanisms and modulation of brain entropy. Larger clinical trials are warranted to validate the potential therapeutic implications of omega-3 PUFAs for deterring cognitive decline in patients with late-life depression,” the study authors concluded.
The study makes an important contribution to the scientific understanding of the effects of omega-3 polyunsaturated fatty acid intake on biological markers in individuals with late-life depression. However, it should be noted that the number of participants was small. It is possible that the treatment produced additional effects, but that these were simply not strong enough to be confidently differentiated from random variations on such a small group of participants.
The paper, “Cognitive protection and brain entropy changes from omega-3 polyunsaturated fatty acids supplement in late-life depression: A 52-week randomized controlled trial”, was authored by Chemin Lin, Shwu-Hua Lee, Chih-Mao Huang, Yu-Wen Wu, You-Xun Chang, HoLing Liu, Shu-Hang Ng, Ying-Chih Cheng, Chih-Chiang Chiu, and Shun-Chi Wu.
